Follow-up to CDC E-Cigarette Weekly Update - Multi-state Call
FDA would like to thank all State Departments of Health (and other partners) for their ongoing efforts, collaboration and communications on the recent pulmonary illness outbreak associated with e-cigarettes and vaping products. As referenced on the September 4th CDC E-Cigarette Weekly Update - Multi-state Call, we are testing samples at our Forensic Chemistry Center (FCC) lab. FCC has a history of partnering with the states and the CDC on domestic and international adverse public health incidents requiring analytical problem solving and is currently engaged in the CDC-FDA-States investigation into a pulmonary illness outbreak and its possible association with vaping.
The FCC is currently prioritizing samples that are most likely to enhance our understanding of this outbreak, i.e., vaping samples that are associated with cases of patient lung injury. If you have identified product samples with direct-association to case-illnesses in your state as part of your ongoing investigations, please reach out your local FDA District Emergency Response Coordinator or write to FDAVapingSampleInquiries@fda.hhs.gov for follow-up, collection, and shipment of samples to FCC through the utilization of FDA field staff.
FCC will provide results directly to the office which submitted the vaping samples once testing results are finalized. Only final, verified results will be released on specific samples.
Moving forward, FCC also plans to issue regular summary updates on its findings to its federal and state partners. The investigation of this outbreak remains an urgent priority for the FDA.